(MENAFN- GlobeNewsWire - Nasdaq) The market surge is driven by Italy's robust public healthcare system, an aging population, and growing demand for early disease diagnosis. Key growth factors include government investment in national screening programs, advancements in laboratory automation, and rising incidence of chronic diseases. However, regional disparities and cost limitations challenge market expansion.

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Italy in-Vitro Diagnostics (IVD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets's offering.
The Italy In-Vitro Diagnostics (IVD) Market was worth USD 2.78 billion in 2024 and is expected to reach USD 5.03 billion by 2033, growing at a CAGR of 6.81% during the period from 2025 to 2033. Italy's IVD market is backed by a well-developed public healthcare system, an aging population, and rising demand for early and precise disease diagnosis. The nation continues to invest in laboratory infrastructure, automation, and molecular testing technologies.

Drivers of Growth in the Italy In-Vitro Diagnostics (IVD) Market

Increasing Incidence of Chronic and Age-Related Diseases: Italy boasts one of the oldest populations in Europe, with a high incidence of chronic diseases like diabetes, cardiovascular diseases, and cancer. This demographic shift greatly boosts the demand for periodic diagnostic testing for early diagnosis and disease control. IVD instruments play a crucial role in tracking patient health, informing treatment decisions, and controlling long-term care. As awareness of preventative healthcare continues to grow, both private and public sectors in Italy are spending more on diagnostics, thus driving long-term demand in clinical laboratories and point-of-care settings. Italy, as per statistics from Eurostat, is the European Union's oldest nation with a median age of over 48. Italy, along with Portugal, also has the highest proportion of people aged over 65, standing at 24%. This translates to about one in every four residents being older than 65.

Government Investment and National Screening Programs: The government of Italy actively promotes public health through different national screening programs for cancers, infectious diseases, and genetic disorders. These programs are highly dependent on in-vitro diagnostics to facilitate early and correct detection. Increased funding for healthcare and harmonization with EU health directives have supported the growth of laboratory facilities and the incorporation of sophisticated diagnostic equipment. Government-sponsored awareness campaigns and free screening programs have greatly contributed to test volumes, making IVD a core element of Italy's healthcare system. December 2024, The Italian Senate has voted on the 2025 budget, which contains a financial package with incentives for innovative antibiotics. Article 49 of the budget law provides new and recently-approved anti-infectives, which are Reserve-classified by the WHO, with access to the national Fund for Innovative Medicines. The Fund will cover up to EUR 100 million annually for the reimbursement of these life-saving antibiotics.

Technological Advancements and Laboratory Automation: Italy's IVD market is undergoing a transition towards automation, digital diagnostics, and molecular testing. Clinical laboratories are embracing sophisticated instruments that enable high-throughput testing, real-time monitoring, and improved diagnostic accuracy. Technologies like CLIA, PCR, and next-generation sequencing are becoming increasingly popular, especially in oncology and infectious disease diagnostics. The push towards operational efficiency and rapid turnaround times is compelling private and public labs to upgrade. This increasing adoption of technology is fortifying the nation's diagnostic strength and boosting market demand. August 2022, DIESSE Diagnostica Senese and Grifols have entered into a partnership to distribute Grifols' Promonitor assays for biological drug monitoring, offered as point-of-care technology or ELISA microplate tests.

Challenges in the Italy In-Vitro Diagnostics (IVD) Market

Regional Disparities in Healthcare Access: Italy's decentralized healthcare system has led to wide regional disparities in the quantity and quality of diagnostic services available. Northern provinces tend to enjoy greater access to sophisticated IVD technologies and properly equipped laboratories, whereas southern regions lack adequate infrastructure and resources. This disparity interferes with even healthcare delivery and limits the entire growth potential of the IVD market. Improvement of these discrepancies necessitates policy reforms and selective investment to allow equal access to diagnostics in every region.

Cost Limitations and Reimbursement Problems: While Italy boasts a publicly funded healthcare system, budget constraints frequently limit access to the most sophisticated and expensive diagnostic tests. Reimbursement is often slow, and not all IVD products are reimbursed in full, particularly new or niche technologies. Such cost-related issues deter wider use of innovative diagnostics and restrict the capacity of private laboratories to replace equipment. Sustaining market growth while balancing innovation with cost-efficiency is a primary challenge.

Key Attributes

Report Attribute	Details
No. of Pages	200
Forecast Period	2024-2033
Estimated Market Value (USD) in 2024	$2.78 Billion
Forecasted Market Value (USD) by 2033	$5.03 Billion
Compound Annual Growth Rate	6.8%
Regions Covered	Italy

Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamic
4.1 Growth Drivers
4.2 Challenges
5. Italy In-Vitro Diagnostics (IVD) Market
6. Market Share
6.1 By Test Types
6.2 By Products
6.3 By Technology
6.4 By Application
6.5 By End User

7. Test Types
7.1 ELISA & CLIA
7.2 PCR
7.3 Rapid Test
7.4 Fluorescence Immunoassays (FIA)
7.5 In Situ Hybridization
7.6 Transcription Mediated Amplification
7.7 Sequencing
7.8 Colorimetric Immunoassay
7.9 Radioimmunoassay (RIA)
7.10 Isothermal Nucleic Acid Amplification Technology
7.11 Others

8. Product Types
8.1 Services
8.2 Instruments
8.3 Reagents

9. Technologies
9.1 Immunoassay
9.2 Clinical Chemistry
9.3 Molecular Diagnostics/Genetics
9.4 Hematology
9.5 Microbiology
9.6 Coagulation
9.7 Others

10. Applications
10.1 Infectious Disease
10.2 Diabetes
10.3 Cardiology
10.4 Oncology
10.5 Nephrology
10.6 Autoimmune Diseases
10.7 Drug Testing
10.8 Other Applications

11. End Users
11.1 Hospitals
11.2 Laboratories
11.3 Home-Care
11.4 Others

12. Porter's Five Forces
12.1 Bargaining Power of Buyer
12.2 Bargaining Power of Supplier
12.3 Threat of New Entrants
12.4 Rivalry among Existing Competitors
12.5 Threat of Substitute Products

13. SWOT Analysis
13.1 Strengths
13.2 Weaknesses
13.3 Opportunities
13.4 Threats

14. Government Rules & Regulation

15. Reimbursement
15.1 Public
15.2 Private & Insurance

16. Key Players Analysis
16.1 Roche Diagnostics
16.2 Abbott Diagnostics
16.3 Siemens Healthineers
16.4 Danaher Corporation
16.5 Thermo Fisher Scientific
16.6 Sysmex Corporation

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Italian in-Vitro Diagnostics (IVD) Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN05112025004107003653ID1110298035